ArticleRegulatory peptides2008
An angiotensin II receptor antagonist reduces inflammatory parameters in two models of colitis.
Article in Regulatory peptides, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025Review
- The Non-Peptide MAS-R Agonist AVE0991 Alleviates Colitis Severity in Mice and Exhibits an Additive Effect with Azathioprine.International journal of molecular sciences · 2025Article
- Modulation of TNF-α, interleukin-6, and interleukin-10 by nebivolol-valsartan and nebivolol-lisinopril polytherapy in SHR rats.Pharmacology research & perspectives · 2024Article
- Unveiling Wide Spectrum Therapeutic Implications and Signaling Mechanisms of Valsartan in Diverse Disorders: A Comprehensive Review.Current drug research reviews · 2024Review
- Repurposing of RAS-Pathway Mediated Drugs for Intestinal Inflammation Related Diseases for Treating SARS-CoV-2 Infection.Current microbiology · 2023Review
- Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats.Saudi journal of biological sciences · 2023Article
- Perindopril/Ambrosin Combination Mitigates Dextran Sulfate Sodium-Induced Colitis in Mice: Crosstalk between Toll-Like Receptor 4, the Pro-Inflammatory Pathways, and SIRT1/PPAR-γ Signaling.Pharmaceuticals (Basel, Switzerland) · 2022Article
- ACE2 in the Gut: The Center of the 2019-nCoV Infected Pathology.Frontiers in molecular biosciences · 2021Review
- The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2017Article
- Blockade of the renin-angiotensin system prevents acute and immunologically relevant colitis in murine models.Pediatric surgery international · 2016Article
- Evaluation of the effect of Punica granatum juice and punicalagin on NFκB modulation in inflammatory bowel disease.Molecular and cellular biochemistry · 2016Article
- Article
- Article
- Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract.Alimentary pharmacology & therapeutics · 2012Review
- Adiponectin and plant-derived mammalian adiponectin homolog exert a protective effect in murine colitis.Digestive diseases and sciences · 2011Article
- Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis.Digestive diseases and sciences · 2011Article
- Role of the xenobiotic receptor in inflammatory bowel disease.Inflammatory bowel diseases · 2011Article
- Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledLittle is known about the effects of the pro-inflammatory hormone Angiotensin II (Ang II) in inflammatory bowel disease. The aim of this study was to evaluate the effect of valsartan (Diovan), an Ang II receptor antagonist, in two models of colitis.
methodsColitis was induced in Sprague-Dawley rats by administration of trinitrobenzene sulfonic acid (TNBS; 30 mg in 50% ETOH i.c.) or 5% Dextran Sulphate Sodium (DSS) in drinking water ad libitum for 5 days. Valsartan was administered orally in drinking water (160 mg/L) during thirty days prior to the induction of the colitis, and for 5 days after. All animals were evaluated for weight change, diarrhea, myeloperoxidase activity, macroscopic and microscopic damage. Cytokine levels in the colon were measured by ELISA, real-time RT-PCR and immunohistochemistry.
resultsIn the TNBS model, valsartan reduced the macroscopic damage score, significantly decreased the microscopic damage (p<0.01), and accelerated weight gain after colitis. In the DSS-colitis model, valsartan-treated animals had less diarrhea and microscopic damage. Valsartan reduced the protein levels of TGFbeta (p<0.05), and IL-18 in the TNBS model, and led to over expression of IL-10 mRNA in the DSS model.
conclusionThese data demonstrate a possible anti-inflammatory effect for valsartan in colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.